The FDA stated today that it wont start gathering new information required from drugmakers under the Coronavirus Aid, Relief, and Economic Security Act next month, though the measure is set to work Sept. 23, Regulatory Focus reported..
” FDA staff are working to define the information to be reported, produce an electronic website for the submission of this details, and determine when to begin collecting this details. We will provide additional updates as our application planning continues,” the FDA said..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.
The CARES Act sets new reporting requirements for drugmakers that are intended to improve the FDAs response to drug shortages. The guidelines need drugmakers to report shortages of drugs that are important to public health throughout a public health emergency as well as the active pharmaceutical ingredients of those drugs..
Though the rule is set to work next month, the FDA states the electronic information submission portal its establishing for drugmakers to send the information will not be ready by then..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
More short articles on pharmacy: Patients over 50 might take meds less if tablet appearance changes a lot, research study saysU.S. cities with the greatest, least expensive prescription drug costsUS takes legal action against Teva for 2nd time in 1 week, this time for alleged price-fixing plan.
Drugmakers are also now required to report making volume data annually, consisting of the quantity of each drug that was produced, prepared, propagated, intensified or processed for industrial circulation, according to Regulatory Focus. The guideline likewise gives HHS the discretion to exempt biologics from some or all of the reporting requirements..
Maia Anderson –
Wednesday, August 26th, 2020
Check out the complete post here..